NOVN Key Statistics, Chart & Performance
The current stock price of NOVN is 0.0941 USD. In the past month the price decreased by -77.43%. In the past year, price decreased by -96.77%.
NOVN Latest News, Press Relases and Analysis
NOVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.94 | 975.93B | ||
| JNJ | JOHNSON & JOHNSON | 19.87 | 496.85B | ||
| MRK | MERCK & CO. INC. | 11.64 | 254.42B | ||
| PFE | PFIZER INC | 8.05 | 146.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.72 | 103.16B | ||
| ZTS | ZOETIS INC | 19.8 | 55.33B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 4.67 | 12.54B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.57 | 8.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.36B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.27B |
Related stock screener links
About NOVN
Company Profile
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
Company Info
NOVAN INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA 27703 US
CEO: Paula Brown Stafford
Employees: 89
Phone: 19194858080.0
NOVAN INC / NOVN FAQ
Can you describe the business of NOVAN INC?
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
What is the stock price of NOVAN INC today?
The current stock price of NOVN is 0.0941 USD. The price decreased by -24.84% in the last trading session.
Does NOVAN INC pay dividends?
NOVN does not pay a dividend.
What is the ChartMill rating of NOVAN INC stock?
NOVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about NOVAN INC (NOVN) stock?
7 analysts have analysed NOVN and the average price target is 15.81 USD. This implies a price increase of 16701.28% is expected in the next year compared to the current price of 0.0941.
What is the next earnings date for NOVN stock?
NOVAN INC (NOVN) will report earnings on 2023-08-09, before the market open.
NOVN Technical Analysis
NOVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NOVN. Both the profitability and financial health of NOVN have multiple concerns.
NOVN Financial Highlights
Over the last trailing twelve months NOVN reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 21.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NOVN Forecast & Estimates
7 analysts have analysed NOVN and the average price target is 15.81 USD. This implies a price increase of 16701.28% is expected in the next year compared to the current price of 0.0941.
For the next year, analysts expect an EPS growth of 78.75% and a revenue growth 19.34% for NOVN